Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
BlueScope Steel Shares Slip After Board Rejects A$13.2 Billion Takeover Bid 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
VANCOUVER, British Columbia, April 06, 2016 -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology, announced today that David Main, Aquinox President & CEO, will present a corporate overview at the upcoming 15th Annual Needham Healthcare Conference in New York city on Wednesday, April 13th, 2016 at 12:10 PM Eastern Time.
A live audio webcast and archive of the event will be available at: http://wsw.com/webcast/needham76/aqxp
To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available on the Investor Relations page of the Aquinox website. The corporate overview being presented will be available following the presentation at www.aqxpharma.com.
About Aquinox Pharmaceuticals, Inc.
Aquinox Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Aquinox's lead drug candidate, AQX-1125, is a small molecule activator of SHIP1 suitable for oral, once daily dosing. With a successful Phase 2 clinical trial completed in 2015, Aquinox plans to initiate a Phase 3 trial in 2016 with AQX-1125 for treatment of interstitial cystitis/bladder pain syndrome (IC/BPS). Aquinox has a broad intellectual property portfolio and pipeline of preclinical drug candidates that activate SHIP1. For more information, please visit www.aqxpharma.com.
Investor Contact Info:
Brendan Payne
Senior Manager, Investor Relations
Aquinox Pharmaceuticals, Inc.
604.629.9223 Ext. 109
[email protected]
Gitanjali Ogawa
Vice President
The Trout Group
646-378-2949
[email protected]
